Physician profile
Michael Cinelli
NPI 1265964696
$16,243.68
in general payments reported to CMS, 2019-2025
14 companies · $7,901 in 2025
The $7,901 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.09 · 2023: $2,809 · 2024: $5,521 · 2025: $7,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,929 · Travel and Lodging: $5,727 · Grant: $2,190 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,929.45 |
| Travel and Lodging | $5,726.88 |
| Grant | $2,189.74 |
| Education | $385.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,487.05 | 2023-2025 | General - Therapies, Watchman Access System, Jetstream Sc |
| Medtronic, INC. | $4,414.13 | 2022-2025 | Corevalve Evolut R, Onyx Frontier, Vitalflow Console |
| Edwards Lifesciences Corporation | $1,860.92 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $871.13 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $754.25 | 2023-2024 | Impella |
| Philips North America LLC | $387.64 | 2023-2025 | (Bq9) Coronary Ivus, Coronary Other |
| Astrazeneca Pharmaceuticals LP | $372.72 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.40 | 2023-2024 | Jardiance |
| Acist Medical Systems, INC. | $204.89 | 2024-2025 | |
| Biotronik INC. | $204.31 | 2024-2025 | Biomonitor, Orsiro Mission |
| Terumo Medical Corporation | $132.72 | 2024-2025 | Angio-Seal, Tr Band, Metacross Otw |
| Teleflex LLC | $130.29 | 2025 | Orsiro Mission |
| Pfizer INC. | $128.66 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $46.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.